Skip to main content

InBody Co.,Ltd (041830.KQ)

KOE Healthcare Medical - SpecialtiesView data quality →
70.4Good

ValueMarkers Composite Index

Top 99%#294 of 44,707
Undervalued

81% below intrinsic value ($109)

UndervaluedFair ValueOvervalued
Piotroski
4/9
Neutral
Beneish
-2.27
Low Risk
Altman
7.99
Safe
DCF Value
$109
Undervalued
ROIC
8.5%
Adequate
P/E
12.8
Value
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

InBody Co.,Ltd (041830.KQ) — VMCI valuation read

InBody Co.,Ltd (041830.KQ) carries a VMCI composite of 70/100, 20 points above the Healthcare sector median of 50. Among mid-cap names, that gap places 041830.KQ in the top third on the five-pillar weighting (Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%).

The 041830.KQ insider tape has been silent for the past 30 days on Form 4. Where executives neither buy nor sell, the bull and bear cases lean harder on filings cadence and the next earnings line.

**Investor frame.** Value reads 041830.KQ trades at 14.0x earnings, 22% below the Healthcare median of 18.0x, which compresses or extends through the 11.0x EV/EBITDA versus a Healthcare 12.0x. Quality: ROIC of 10.0% sits 0.0pp above the Healthcare median (10.0%). Risk: net debt to EBITDA of -1.5x leaves covenant headroom, the line to track on InBody Co.,Ltd's next 10-Q.

041830.KQ fell 0.3% over the trailing 7 days, with a -9.5% read on a 30-day basis.

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in 041830.KQ’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.